Escolar Documentos
Profissional Documentos
Cultura Documentos
From the 1Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at HarborUCLA Medical Center, Torrance, California; the 2 Institute of Pathophysiology,
Semmelweis University, Budapest, Hungary; the 3Division of Nephrology,
Salem VA Medical Center, Salem, Virginia; the 4Division of Nephrology,
University of Virginia, Charlottesville, Virginia; the 5Division of Nephrology
and Hypertension, HarborUCLA Medical Center, Torrance, California;
6
DaVita Inc., Denver, Colorado; the 7David Geffen School of Medicine at
UCLA, Los Angeles, California; the 8Renal Unit, Joslin Diabetes Center,
Harvard Medical School, Boston, Massachusetts; and the 9Department of
Epidemiology, UCLA School of Public Health, Los Angeles, California.
Corresponding author: Kamyar Kalantar-Zadeh, kamkal@ucla.edu.
Received 19 July 2011 and accepted 1 December 2011.
DOI: 10.2337/db11-1015
This article contains Supplementary Data online at http://diabetes
.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1015/-/DC1.
J.R. and M.Z.M. contributed equally to this work.
2012 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for prot,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
708
cardiovascular complications, including myocardial infarctions and hospitalizations for coronary artery disease
(1,8). Some guidelines, such as those of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI), have recommended that diabetic dialysis
patients should follow the American Diabetes Association
guidelines; however, there is no consistent evidence to
support these recommendations for patients with ESRD (9
12). This lack of evidence is highlighted by the KDOQI
recommendations, last updated in 2007, stating that target
A1C for people with diabetes should be ,7%, irrespective of
presence or absence CKD [chronic kidney disease] (13).
There are several issues unique to the dialysis population that obligate a separate examination of glycemic
control on outcomes in this cohort. Insulin and glucose
homeostasis are affected by uremia, which may aggravate
insulin resistance (14). Moreover, it may be difcult to
accurately assess glycemic control in this population because of changes in erythrocyte survival in renal failure
and the effects of erythropoiesis-stimulating agents on A1C
levels (14,15).
Recently, three large randomized trials have indicated
that intensive glucose lowering in patients with type 2 diabetes did not reduce the risks of cardiovascular disease,
the most common source of ESRD mortality (1619). Additionally, Williams and colleagues (20,21) reported a higher
risk of death only in diabetic hemodialysis patients with
A1C levels .11%. Shurraw et al. (22) found that higher
casual glucose and A1C levels were not associated with
mortality in maintenance hemodialysis (MHD) patients
with or without diabetes. In contrast, we reported that
after adjusting for potential confounders, higher A1C values were incrementally associated with higher death risks
in patients on MHD (23). These large observational studies
with differing methodologies and recruited patient populations reached somewhat contrasting conclusions regarding the association of A1C with survival in diabetic
MHD patients. Hence, we undertook this study to further
examine the predictive value of glycemic control on allcause and cardiovascular mortality in a large, contemporary cohort of MHD patients. This extended cohort study
also adds data on glucose levels, examines the effects of
anemia and race, and provides new subset analyses.
RESEARCH DESIGN AND METHODS
We extracted, rened, and examined data from all individuals with ESRD who
underwent MHD treatment from July 2001 through June 2006 in any 1 of the 580
outpatient dialysis facilities of DaVita Inc., a large dialysis organization in the
U.S. (before its acquisition of units owned by Gambro). The study was approved
by relevant institutional review committees. Patients were included who had
been undergoing dialysis for at least 90 days, were being treated with MHD at
diabetes.diabetesjournals.org
the time of entry into the cohort, had a history of diabetes, and had at least one
A1C measurement in the rst quarter of entry into the cohort.
Clinical and demographic measures. The creation of the cohort has previously been described (2426). To minimize measurement variability, all repeated measures for each patient during any given calendar quarter, i.e., over
a 13-week interval, were averaged and values were used in all models. Average
values were obtained from up to 20 calendar quarters (q1q20) for each laboratory and clinical measure for each patient over the 6-year cohort period.
The rst (baseline) studied quarter for each patient was the calendar quarter
in which the patients vintage reached .90 days. The presence or absence of
diabetes at baseline was obtained from DaVita Inc. data. Histories of tobacco
smoking and preexisting comorbid conditions were obtained by linking the
DaVita Inc. database to the Medical Evidence Form 2728 of the United States
Renal Data System, and the latter were categorized into 10 comorbid conditions:
ischemic heart disease, congestive heart failure, history of cardiac arrest, history
of myocardial infarction, pericarditis, cardiac dysrhythmia, cerebrovascular
events, peripheral vascular disease, chronic obstructive pulmonary disease, and
cancer (27).
Patients were followed for outcomes through 30 June 2007. The recorded
causes of death were obtained from the United States Renal Data System, and
cardiovascular death was dened as death due to myocardial infarction,
cardiac arrest, heart failure, cerebrovascular accident, and other cardiac
causes.
Laboratory measures. Blood samples were drawn using uniform techniques
in all dialysis clinics and were transported to the DaVita Laboratory in Deland,
Florida, within 24 h. All laboratory values, including A1C, were measured by
automated and standardized methods. Most laboratory values were measured
monthly. A1C was usually measured quarterly or semiannually. We divided
patients into seven a priori categories based on A1C values: ,5 and $10% and
1% increments in between, to examine the dose-response association between
A1C categories and death risk. Additional analyses were performed after
subdividing the population into two groups of A1C $7 and ,7 and A1C $6
and ,6%. We divided patients into eight a priori categories based upon randomly measured serum glucose values (,100, 100 to ,125, 125 to ,150, 150
to ,175, 175 to ,200, 200 to ,250, 250 to ,300, and $300 mg/dL) to examine
the dose-response association between glucose categories and death risk.
Finally, additional analyses were performed after dividing the population into
two subgroups of glucose: $150 and ,150 mg/dL.
Epidemiologic and statistical methods. Survival analyses with Cox proportional hazards regression with repeated quarterly measures were used to
examine whether glycemic control predicted survival for up to 6 years of
follow-up. The primary analysis examined the associations between baseline
A1C and glucose and all-cause mortality, with cardiovascular mortality serving
as a secondary outcome measure. We also performed exploratory analyses in
subgroups of patients based on age, sex, race, dialysis vintage, serum albumin
category (#3.8 or .3.8 g/dL), and anemia (serum hemoglobin #11 or .11 g/dL
and serum ferritin #500 or .500 ng/mL). We also performed exploratory
analyses according to race. To analyze the predictive value of time-averaged
A1C and glucose and assess the association between different laboratory and
clinical parameters and A1C levels, logistic regression analyses were performed. For each analysis, including subgroup analyses, three models were
examined:
1) Unadjusted model that included mortality data, A1C/glucose categories,
and entry calendar quarter (q1q20).
2) Case-mixadjusted model that included all of the above plus age, sex, race/
ethnicity (African Americans and other self-categorized Blacks, Non-Hispanic
Caucasians, Asians, Hispanics, and others), categories of dialysis vintage
(,6 months, 6 months to 2 years, 25 years, and $5 years), primary insurance (Medicare, Medicaid, private, and others), marital status (married,
single, divorced, widowed, and other or unknown), dialysis dose as indicated by Kt/V (single pool), and residual renal function during the entry
quarter, i.e., urinary urea clearance.
3) Case-mix plus malnutrition-inammation-complex syndrome (MICS)adjusted
model, which included all of the covariates in the case-mix model as well as
12 surrogates of nutritional status and inammation, including BMI, total
nitrogen appearance (also known as normalized protein catabolic rate
[nPCR]), and 10 laboratory surrogates with known association with clinical
outcomes in hemodialysis patients (28) including serum levels of albumin,
total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bicarbonate, white blood cell count, lymphocyte percentage, and hemoglobin.
Missing covariate data were imputed by the multivariate regression imputation method as appropriate. For all analysis, two-sided P values are reported
and results considered statistically signicant if P , 0.05. All statistical analyses were carried out with SAS, version 9.1 (SAS Institute, Cary, NC).
diabetes.diabetesjournals.org
RESULTS
709
710
81
4.8
8.8
6
13
4.3
31
23
1.6
4.1
6.5
6
6
6
6
6
6
6
6
6
6
6
6
6
82
4.0
8.9
5.9
15
3.2
34
25
1.2
4.0
5.8
6
6
6
6
6
6
6
6
6
6
6
6
6
0.35
0.51
2.9
50
3.1
1.5
0.73
487
0.26
1.4
7.9
7.3
22
37
7
19
17
40
7
20
14
1.5
3.6
7.5
197
23
5.4
9.1
547
0.91
12
20
28
75
14
27
36
23
65
14
30
37
19
64
0.34
0.44
2.9
46
3.0
1.4
0.67
462
0.26
1.3
7.6
7.1
22
40
34
15
3
40
30
19
3
1.5
3.6
7.5
209
23
5.5
9.1
496
0.96
12
20
27
78
5,800
65 6 13
51
54,757
63 6 13
49
,5
1.5
3.6
7.2
207
23
5.4
9.1
502
0.94
12
20
28
77
6
6
6
6
6
6
6
6
6
6
6
6
6
0.36
0.46
2.8
48
3.0
1.4
0.64
464
0.26
1.4
7.7
7.0
21
82
4.8
9.5
7
15
4
35
26
1.6
4.1
6.4
40
7
19
16
15
30
36
19
66
41
31
17
3
15,993
66 6 12
49
5 to ,6
Data are means 6 SD or percent unless otherwise indicated. WBCs, white blood cells.
N
Age (years)
Sex (% female)
Race
White
Black
Hispanic
Asian
Dialysis vintage
06 months
624 months
25 years
.5 years
Primary insurance Medicare
Marital status
Married
Divorced
Single
Widowed
Comorbidities upon dialysis initiation
Hypertension
Inability to ambulate
Cerebrovascular disease
Other cardiac disease
Peripheral vascular disease
Malignant neoplasm, cancer
Congestive heart failure
Atherosclerotic heart disease
Inability to transfer
Tobacco use
Pulmonary disease
Laboratory values
Delivered single-pool Kt/V
Serum albumin (g/dL)
Creatinine (mg/dL)
Total iron-binding capacity (mg/dL)
Bicarbonate (mg/dL)
Phosphorus (mg/dL)
Calcium (mg/dL)
Ferritin (ng/mL)
Protein catabolic rate (g/kg/day)
Blood hemoglobin (g/dL)
Lymphocyte (% of total WBCs)
BMI (kg/m2)
Weight (kg)
All patients
1.5
3.6
7.2
212
23
5.5
9.1
496
0.97
12
20
28
79
6
6
6
6
6
6
6
6
6
6
6
6
6
0.36
0.43
2.8
46
3.0
1.4
0.69
477
0.26
1.3
7.5
7.2
22
81
4.1
9.2
6.3
15
3.3
35
27
1.2
3.7
6.1
42
7
19
14
15
31
36
18
64
41
29
19
3
14,988
64 6 12
48
6 to ,7
1.5
3.6
7.2
214
22
5.5
9.1
481
0.98
12
20
29
80
6
6
6
6
6
6
6
6
6
6
6
6
6
0.36
0.41
2.7
43
3.0
1.4
0.66
440
0.26
1.3
7.4
7.5
22
82
3.6
8.8
5.4
15
2.6
34
26
1
3.7
5.4
41
8
19
12
13
32
36
19
62
39
28
21
3
8,788
62 6 12
49
A1C (%)
7 to ,8
TABLE 1
Demographic, clinical, and laboratory values in 54,757 MHD patients and according to the categories of A1C
1.5
3.6
7.2
215
22
5.6
9.1
481
0.98
12
21
29
80
6
6
6
6
6
6
6
6
6
6
6
6
6
0.37
0.42
2.8
42
2.9
1.4
0.64
450
0.26
1.3
7.4
7.2
22
82
2.7
7.7
4.8
15
2
33
24
0.55
4.2
4.8
42
7
22
11
12
31
38
19
60
37
29
23
3
4,679
59 6 13
49
8 to ,9
1.5
3.6
7.2
215
22
5.7
9.1
457
0.98
12
21
28
79
6
6
6
6
6
6
6
6
6
6
6
6
6
0.38
0.41
2.7
42
2.9
1.4
0.67
399
0.26
1.3
7.2
7.1
21
82
2.2
7.7
4.4
15
1.7
31
22
0.76
5
4.2
41
8
25
9
12
33
38
17
58
35
30
23
2
2,405
57 6 13
48
9 to ,10
1.5
3.5
7.1
210
22
58
9.0
479
0.96
12
21
28
79
6
6
6
6
6
6
6
6
6
6
6
6
6
0.36
0.43
2.7
41
2.9
1.4
0.64
446
0.25
1.3
7.4
7.2
22
83
1.7
7
3.7
14
1.3
32
20
0.38
5.8
3.7
38
8
28
7
12
33
37
18
58
31
35
22
2
2,104
54 6 13
48
$10
0.65
,0.0001
0.64
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
0.06
,0.001
,0.001
,0.001
0.19
,0.001
0.21
,0.001
,0.001
0.003
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
,0.001
0.05
,0.001
,0.001
,0.001
,0.001
,0.001
0.29
,0.001
0.11
diabetes.diabetesjournals.org
FIG. 1. HRs of all-cause mortality of the entire range of A1C in 54,757 MHD patients using standard Cox proportional hazards regression (A),
a time-averaged model (B), and HRs of all-cause mortality of serum glucose in 50,383 diabetic MHD patients using standard Cox proportional
hazards regression (C) and a time-averaged model (D). Case-mix model is adjusted for age, sex, race and ethnicity, categories of dialysis vintage,
primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), and residual renal function during the entry quarter. MICSadjusted model includes all of the case-mix covariates as well as BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bicarbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
711
FIG. 2. HRs of all-cause mortality for the dichotomized A1C >7% in different subgroups of 54,757 MHD patients (A) and HRs of all-cause mortality
for the dichotomized glucose >150 mg/dL in different subgroups of 50,383 MHD patients (B). Fully adjusted model is controlled for age, sex, race
and ethnicity, categories of dialysis vintage, primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), residual renal
function during the entry quarter, BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bicarbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
MICS variables. A baseline glucose $150 mg/dL was associated with higher mortality risk in Hispanic patients and
patients with albumin ,3.8 g/dL.
We repeated the analyses using cardiovascular death as
the outcome. Figure 3C and D shows unadjusted and adjusted HRs according to the baseline and time-averaged
glucose values. Similarly to all-cause mortality, cardiovascular mortality risk was associated with a baseline glucose
$300 mg/dL and a time-averaged glucose $200 mg/dL.
Correlates of low A1C. To examine the likelihood of
unusually low A1C in diabetic HD patients, we performed
a multivariate logistic regression analysis comparing the
odds of low (,6%) A1C to the nonlow A1C group ($6%)
(Table 2). In our case-mixadjusted model, each gram per
deciliter increase in serum albumin (odds ratio 0.90 [0.86
0.94]) and blood hemoglobin level (0.87 [0.860.88]), each
gram per kilogram per day increase of nPCR (0.55 [0.51
0.59]), and each kilogram per meters squared increase in
BMI level (0.93 [0.920.94]) translated into a 10, 13, 45, and
7% lower risk of A1C level ,6%, respectively.
DISCUSSION
In this large-scale and contemporary cohort of 54,757 diabetic MHD patients, we report that a time-averaged A1C
$8% or time-averaged serum glucose $200 mg/dL appears
to be associated with higher all-cause and cardiovascular
mortality. This association was particularly robust in diabetic MHD patients with hemoglobin levels $11 g/dL.
Subgroup analyses showed that the baseline A1C threshold for higher all-cause mortality was higher in Caucasians,
men, and patients with albumin level ,3.8 g/dL (A1C $7%).
We also report that the likelihood of having low baseline
A1C (,6%) was associated with lower values for BMI, albumin, creatinine, and nPCR levels, indicating a link between A1C level and malnutrition and inammation burden.
These ndings may have important clinical implications,
especially since they imply that moderate hyperglycemia
may not be a risk factor for death for this population.
The literature on the relationship between glycemic control and survival in CKD population is somewhat limited.
712
FIG. 3. HRs of cardiovascular mortality of the entire range of A1C in 54,757 MHD patients using standard Cox proportional hazards regression (A),
a time-averaged model (B), and HRs of cardiovascular mortality of serum glucose in 50,383 diabetic MHD patients using standard Cox proportional
hazards regression (C) and a time-averaged model (D). Case-mix model is adjusted for age, sex, race and ethnicity, categories of dialysis vintage,
primary insurance, marital status, dialysis dose as indicated by Kt/V (single pool), and residual renal function during the entry quarter. MICSadjusted model includes all of the case-mix covariates as well as BMI, nPCR, serum levels of albumin, total iron-binding capacity, ferritin, creatinine, phosphorus, calcium, bicarbonate, blood white blood cell count, lymphocyte percentage, and hemoglobin.
for hypoglycemic episodes, which with increasing frequency increases the risk of dying in the long-term followup period. Another potential explanation is that low A1C
level is a surrogate marker of protein-energy wasting,
which is a well-know predictor of mortality in MHD
patients (35). This was supported by our observations. In
our logistic regression model, the markers of proteinenergy wasting such as albumin, creatinine, and BMI indicated a correlation with having a low A1C level. After
adjusting the MICS covariables, we found that this association was abolished or sometimes inversed, indicating
that MICS is in the causal pathway.
The information on comorbidity in our study was limited
to that obtained from Medical Evidence Form 2728, a form
through which comorbid conditions are signicantly underreported (36). Moreover, we did not have any data
available on the medications, if any, to treat diabetes or
their doses, and we did not study patient adherence with
therapy. Furthermore, the required dose of these medications can be confounded by the residual renal function
and its deterioration over time (37). Another potential
DIABETES, VOL. 61, MARCH 2012
713
TABLE 2
Multivariate logistic regression models showing clinical parameters and their odds ratios (95% CI) for low (,6%) A1C compared with
the nonlow A1C group ($6%) as reference
Unadjusted
Case-mix adjusted
1.02 (1.021.03)
1.04 (1.001.07)
1.03 (1.021.03)
0.98 (0.941.02)
1.03 (1.031.03)
1.00 (0.961.04)
Reference
1.15 (1.111.19)
0.77 (0.740.81)
0.92 (0.831.01)
Reference
1.07 (1.021.11)
0.79 (0.750.83)
0.82 (0.740.91)
Reference
0.91 (0.870.96)
0.79 (0.750.84)
0.78 (0.700.87)
Reference
0.90 (0.870.93)
0.98 (0.951.02)
1.13 (1.081.18)
Reference
0.93 (0.880.98)
1.02 (0.961.08)
1.16 (1.081.23)
Reference
0.95 (0.901.01)
0.96 (0.911.02)
0.93 (0.861.00)
Reference
0.90 (0.830.97)
0.96 (0.911.02)
0.77 (0.730.81)
Reference
1.13 (1.041.23)
1.02 (0.961.08)
0.87 (0.820.92)
Reference
1.12 (1.031.22)
1.02 (0.961.09)
0.94 (0.890.99)
Reference
0.90 (0.840.96)
0.92 (0.880.96)
1.33 (1.271.40)
Reference
0.98 (0.911.05)
1.09 (1.041.14)
1.06 (1.001.12)
Reference
0.97 (0.901.04)
1.08 (1.031.13)
1.04 (0.991.10)
1.00
1.40
1.09
1.21
0.94
1.55
0.98
0.98
1.68
1.03
1.20
(0.951.04)
(1.281.52)
(1.031.16)
(1.121.30)
(0.900.99)
(1.411.71)
(0.941.10)
(0.941.02)
(1.441.96)
(0.941.12)
(1.121.30)
1.01
1.26
1.00
1.12
0.90
1.30
0.90
0.88
1.27
1.15
1.09
(0.971.06)
(1.141.40)
(0.941.07)
(1.031.20)
(0.860.95)
(1.181.44)
(0.870.94)
(0.840.92)
(1.061.52)
(1.051.26)
(1.011.18)
1.02
1.25
1.00
1.13
0.90
1.24
0.94
0.89
1.25
1.12
1.13
(0.971.06)
(1.131.39)
(0.941.06)
(1.041.22)
(0.850.95)
(1.121.37)
(0.900.98)
(0.850.93)
(1.041.50)
(1.021.23)
(1.041.22)
0.98
0.90
1.02
0.68
1.02
0.95
1.08
0.54
0.87
1.00
0.92
(0.931.02)
(0.870.94)
(1.011.02)
(0.670.69)
(1.011.03)
(0.940.96)
(1.051.10)
(0.510.58)
(0.860.88)
(0.991.00)
(0.910.92)
0.90
0.90
1.05
0.73
1.00
1.00
1.04
0.55
0.87
1.00
0.93
(0.860.95)
(0.860.94)
(1.041.06)
(0.710.74)
(0.991.01)
(0.991.01)
(1.011.06)
(0.510.59)
(0.860.88)
(1.001.01)
(0.920.94)
1.12
1.09
1.08
0.78
0.99
1.01
1.09
0.45
0.87
1.00
0.93
(1.051.19)
(1.031.15)
(1.071.09)
(0.760.78)
(0.981.00)
(0.991.02)
(1.061.12)
(0.410.49)
(0.860.88)
(1.001.00)
(0.920.94)
In conclusion, poor glycemic control (A1C $8% or serum glucose $200 mg/dL) appears to be associated with
decreased survival in the general population of diabetic
MHD patients. Our study suggests that moderate hyperglycemia increases the risk for all-cause or cardiovascular
mortality of diabetic MHD patients, especially in certain
subgroups (Caucasians, men, and those with serum albumin #3.8 g/dL). Moreover, the presence of protein-energy
wasting contributes to the higher risk of low (,6%) A1C
level. Admittedly, mortality is only one measure of the
deleterious impact of poor glycemic control. Other potential benets of glycemic control, including slowing the
rate of progression of microvascular disease and rate of
loss of residual renal function, are possible and were not
diabetes.diabetesjournals.org
715